The mechanism of action of Semaglutide injection is that it is a GLP-1 receptor agonist that activates GLP-1 receptors in the brain, pancreas, and gastrointestinal tract. By binding to these receptors, Semaglutide Injection stimulates insulin secretion, reduces glucagon secretion, and slows gastric emptying. These actions lead to improved glucose control, reduced appetite, and increased satiety. In addition, Semaglutide Injection has been shown to regulate the reward system in the brain, reducing cravings and promoting healthier food choices. The efficacy of Semaglutide injections for weight management has seen our patients lose on average 15.3% of their body weight over 68 weeks. This is a significant improvement compared to other weight-loss medications and interventions, such as orlistat and lifestyle modifications. However, Semaglutide Injection is not without adverse effects, including gastrointestinal symptoms, pancreatitis, and thyroid cancer. Therefore, careful patient selection and monitoring are necessary. Semaglutide Injection is not suitable for all patients, and careful consideration should be given to patient selection and contraindications. Patients with a history of pancreatitis or thyroid cancer should not use Semaglutide injections. Dosage and administration guidelines should be followed closely to ensure optimal efficacy and safety. The cost-effectiveness and accessibility of Semaglutide Injection as a weight loss treatment should also be considered, as it may not be affordable or available to all patients.